With understandable fanfare, SurModics recently announced a deal with Roche and Genentech for the delivery of injected Lucentis – an antibody treatment for wet age-related macular degeneration (AMD) with $2 billion in annual sales – using SurModic's biodegradable microparticles for sustained release...
This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!
News Commentary | May 24, 2021
This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription
News Commentary | September 08, 2021
Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription
Company Profile | December 01, 2021
Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription